Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hainan Huluwa Pharmaceutical Group (605199) Fair Value & Analysis

Healthcare · CN · Market cap 2.5B CNY

Price¥5.89
Fair Value¥1.17
Upside-80.1%
Quality93/100
Evidence: Medium Range ¥0.8200 – ¥1.96

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Hainan Huluwa Pharmaceutical Group (605199) currently trades at ¥5.89, while our model-based Fair Value estimate is ¥1.17 — implying the stock looks roughly 80.1% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of Children's digestive system, respiratory system, anti-infection, anti-virus and other fields in China. The company offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. Hainan Huluwa Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Haikou, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Hainan Huluwa Pharmaceutical Group (605199) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥1.17 versus a price of ¥5.89 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 605199?
Our 21-model fair value for Hainan Huluwa Pharmaceutical Group is ¥1.17 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥5.89.
What is the quality score of 605199?
Hainan Huluwa Pharmaceutical Group has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.